These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28853141)

  • 21. Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.
    de Jongh M; Eyck BM; van der Werf LR; Toxopeus ELA; van Lanschot JJB; Lagarde SM; van der Gaast A; Nuyttens J; Wijnhoven BPL
    BJS Open; 2021 Mar; 5(2):. PubMed ID: 33876211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
    Fang P; Jiang W; Davuluri R; Xu C; Krishnan S; Mohan R; Koong AC; Hsu CC; Lin SH
    Radiother Oncol; 2018 Sep; 128(3):584-590. PubMed ID: 29530432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
    Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
    Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
    Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
    Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching.
    Zhang Y; Sun Y; Xu Z; Chi P; Lu X
    Eur J Surg Oncol; 2017 Aug; 43(8):1440-1446. PubMed ID: 28502421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
    Ruffier-Loubière A; Janoray G; Chapet S; de Calan L; Dumont P; Dorval É; Orain I; Calais G
    Cancer Radiother; 2015 Aug; 19(5):322-30. PubMed ID: 26215366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer.
    Hamai Y; Hihara J; Emi M; Murakami Y; Kenjo M; Nagata Y; Okada M
    Ann Thorac Surg; 2015 Jun; 99(6):1887-93. PubMed ID: 25912745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
    Lin G; Han SY; Xu YP; Mao WM
    Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
    Kim MK; Cho KJ; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Song HJ; Ryu JS; Kim SB
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):115-21. PubMed ID: 19251379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex Disparities After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer.
    Rowse PG; Jaroszewski DE; Thomas M; Harold K; Harmsen WS; Shen KR
    Ann Thorac Surg; 2017 Oct; 104(4):1147-1152. PubMed ID: 28842111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Esophageal cancer: outcome according to therapeutic strategy].
    Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
    Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trimodality treatment versus surgery alone for esophageal cancer. A stratified analysis with minimally invasive pretreatment staging.
    Jiao X; Sonett J; Gamliel Z; Doyle A; Schuetz J; Greenwald B; Suntharalingam M; Krasna MJ
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):531-7. PubMed ID: 12124569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study.
    van der Woude SO; Hulshof MC; van Laarhoven HW
    Chin Clin Oncol; 2016 Feb; 5(1):13. PubMed ID: 26932437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis.
    Metzger JC; Wollschläger D; Miederer M; Vaupel P; Moehler M; Schmidberger H; Mayer A
    Strahlenther Onkol; 2017 Oct; 193(10):791-799. PubMed ID: 28770295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
    Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
    Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
    Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer?
    Voncken FE; Jiang H; Kim J; Guindi M; Brierley J; Knox J; Liu G; Horgan AM; Lister J; Darling G; Metser U; Wong RK
    Dis Esophagus; 2014 Aug; 27(6):552-9. PubMed ID: 23121504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.